LB1901

About Genscript Biotech

Founded in 2002, GenScript Biotech has evolved from a gene synthesis pioneer into a $24+ billion market cap global platform, serving over 200,000 clients worldwide. Its mission is to make biology easier and accelerate the transition from discovery to therapy. The company's strategy leverages its dominant Life Science Services segment as a powerful funnel to drive growth in its high-value Biologics CDMO and Cell Therapy businesses, creating a unique, synergistic ecosystem.

About Legend Biotech

Legend Biotech's mission is to discover, develop, and commercialize transformative cell therapies for patients with life-threatening diseases, primarily in oncology. Its core achievement is the successful global launch of CARVYKTI® (cilta-cel), a best-in-class CAR-T therapy for multiple myeloma, which has propelled the company to commercial leadership and validated its technology platform. The company's strategy centers on deepening its commercial footprint, advancing a broad pipeline of next-generation cell therapies, and expanding its manufacturing capabilities, all underpinned by a strategic global collaboration with Janssen (Johnson & Johnson).

Therapeutic Areas